Pfizer's Ambitious Oncology Roadmap: Welcoming a New Commercial Leader to Drive Growth

Pfizer is set to welcome a new leader for its oncology business, who will take on the responsibility of helping the company achieve its ambitious goal of having 8 major impact oncology drugs by 2030. This goal reflects Pfizer's steadfast commitment and long-term vision in the field of cancer treatment.

Suneet Varma, the current Oncology Business Unit President, has been with Pfizer for 15 years and has made significant contributions to the company's development. He will now retire and enjoy a peaceful retirement. His successor, Tina Deigna, previously served as the Senior Vice President of Novartis' US Oncology business, bringing extensive industry experience and expertise. She will officially take up her new role at Pfizer this fall. To ensure a smooth transition, Suneet Varma will continue working until early 2025 to facilitate a seamless handover.

Following the successful acquisition of Seagen, Pfizer has realigned its oncology strategy. By 2030, Pfizer aims for two-thirds of its oncology revenue to come from new molecular entities and new indications for existing products. This means the company will increase its investment in new drug development over the next few years to achieve the goal of having at least 8 major cancer-fighting drugs.

Tina Deigna not only excelled at Novartis but also spent 15 years at BMS, where she was deeply involved in oncology research and development, and successfully led the launch of BMS's "landmark cancer immunotherapy indications." This experience will provide valuable guidance for her new role at Pfizer.

With Tina Deigna on board, Pfizer's ambitious plans in the oncology field are poised for further realization. Her expertise and extensive experience will infuse new vitality into the company's development, helping Pfizer achieve more breakthroughs and successes in cancer treatment. We have every reason to believe that under Tina Deigna's leadership, Pfizer will enter a new golden era, bringing more effective treatment options to cancer patients worldwide and making a greater contribution to global health.